antibodies against brd2 (Cell Signaling Technology Inc)
Cell Signaling Technology Inc is a verified supplier 
Cell Signaling Technology Inc manufactures this product 
86
Structured Review
Cell Signaling Technology Inc
antibodies against brd2
Antibodies Against Brd2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/brd2+antibody/pm41773861-58-0-31
Average 86 stars, based on 1 article reviews
Antibodies Against Brd2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/brd2+antibody/pm41773861-58-0-31
Average 86 stars, based on 1 article reviews
antibodies against brd2 - by Bioz Stars,
2026-10
86/100 stars
Images
Related Articles
Incubation:Article Title: Synthetic lethal and resistance interactions with BET bromodomain inhibitors in triple-negative breast cancer Article Snippet: Cells were pelleted and resuspended in 1ml LB3 buffer (10 mM Tris-HCl [pH 7.4], 1 mM EDTA, 0.1%SDS, 1%Triton X-100, 0.1% Na-deoxycholate, 1Mm DTT, 0.25% N-lauroylsarcosine, protease inhibitors and phosphatase inhibitors) and sonicated in a Covaris sonicator for 10 min. A total of 30 μl of 5M NaCl was added, and lysate was centrifuged for 10 min at 20,000 rcf to purify the debris. .. The supernatant was then incubated with 50 μl of magnetic beads (Life Technologies) prebound with 20 μg BRD4 antibody (Bethyl, A301–985A), 20 μl Magnetic Beads:Article Title: Synthetic lethal and resistance interactions with BET bromodomain inhibitors in triple-negative breast cancer Article Snippet: Cells were pelleted and resuspended in 1ml LB3 buffer (10 mM Tris-HCl [pH 7.4], 1 mM EDTA, 0.1%SDS, 1%Triton X-100, 0.1% Na-deoxycholate, 1Mm DTT, 0.25% N-lauroylsarcosine, protease inhibitors and phosphatase inhibitors) and sonicated in a Covaris sonicator for 10 min. A total of 30 μl of 5M NaCl was added, and lysate was centrifuged for 10 min at 20,000 rcf to purify the debris. .. The supernatant was then incubated with 50 μl of magnetic beads (Life Technologies) prebound with 20 μg BRD4 antibody (Bethyl, A301–985A), 20 μl Immunoprecipitation:Article Title: Synthetic lethal and resistance interactions with BET bromodomain inhibitors in triple-negative breast cancer Article Snippet: Cells were pelleted and resuspended in 1ml LB3 buffer (10 mM Tris-HCl [pH 7.4], 1 mM EDTA, 0.1%SDS, 1%Triton X-100, 0.1% Na-deoxycholate, 1Mm DTT, 0.25% N-lauroylsarcosine, protease inhibitors and phosphatase inhibitors) and sonicated in a Covaris sonicator for 10 min. A total of 30 μl of 5M NaCl was added, and lysate was centrifuged for 10 min at 20,000 rcf to purify the debris. .. The supernatant was then incubated with 50 μl of magnetic beads (Life Technologies) prebound with 20 μg BRD4 antibody (Bethyl, A301–985A), 20 μl other:Article Title: BRD4 regulates cellular senescence in gastric cancer cells via E2F/miR-106b/p21 axis Article Snippet: BRD2 and Article Title: The epigenetic reader Brd4 is required for osteoblast differentiation. Article Snippet: Antibodies and concentrations used for western blot analysis were as follows: Brd2 (Cell Signaling; Cat #D89B4 1:1000), Brd4 (Bethyl Labs; Cat #A301‐985A; 1:2,000), Article Title: Physachenolide C is a Potent, Selective BET Inhibitor. Article Snippet: A pulldown using a biotinylated natural product of interest in the 17β-hydroxywithanolide (17-BHW) class, physachenolide C (PCC), identified the bromodomain and extra-terminal domain (BET) family of proteins (BRD2, BRD3, and BRD4), readers of acetyllysine modifications and regulators of gene transcription, as potential cellular targets.. BROMOscan bromodomain profiling and biochemical assays support PCC as a BET inhibitor with increased selectivity for bromodomain (BD)-1 of BRD3 and BRD4, and X-ray crystallography and NMR studies uncovered specific contacts that underlie the potency and selectivity of PCC toward BRD3-BD1 over BRD3-BD2.. PCC also displays characteristics of a molecular glue, facilitating proteasomemediated degradation of BRD3 and BRD4. |
